(Q34863985)

5 August 2017

1 reference

title

Current topics and perspectives relating to hormone therapy for prostate cancer (English)

1 reference

5 August 2017

1 reference

Hiroyoshi Suzuki

1

1 reference

5 August 2017

Naoto Kamiya

2

1 reference

5 August 2017

Takashi Imamoto

3

1 reference

5 August 2017

Koji Kawamura

4

1 reference

5 August 2017

Masashi Yano

5

1 reference

5 August 2017

Makoto Takano

6

1 reference

5 August 2017

Takanobu Utsumi

7

1 reference

5 August 2017

Yukio Naya

8

1 reference

5 August 2017

Tomohiko Ichikawa

9

1 reference

5 August 2017

23 October 2008

1 reference

International Journal of Clinical Oncology

5 August 2017

1 reference

5 August 2017

13

1 reference

5 August 2017

401-410

1 reference

5 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-008-0830-y

5 August 2017

0 references

cites work

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10147-008-0830-Y

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

21 January 2018

1 reference

12 December 2020

Androgen receptor involvement in the progression of prostate cancer

1 reference

12 December 2020

Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer

1 reference

12 December 2020

Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.

1 reference

12 December 2020

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

12 December 2020

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

12 December 2020

Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

1 reference

12 December 2020

Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study

1 reference

12 December 2020

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.

1 reference

12 December 2020

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

1 reference

12 December 2020

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

1 reference

12 December 2020

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

1 reference

12 December 2020

Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer

1 reference

12 December 2020

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors

1 reference

12 December 2020

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

1 reference

12 December 2020

International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients

1 reference

12 December 2020

Should intermittent androgen deprivation be used in routine clinical practice?

1 reference

12 December 2020

The role of testosterone in the pathogenesis of prostate cancer

1 reference

12 December 2020

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

1 reference

12 December 2020

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

12 December 2020

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer

1 reference

12 December 2020

CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer

1 reference

12 December 2020

Endocrine treatment of prostate cancer

1 reference

12 December 2020

Quality of life issues relating to endocrine treatment options.

1 reference

12 December 2020

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No.

1 reference

12 December 2020

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

12 December 2020

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

12 December 2020

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Intermittent endocrine therapy for advanced prostate cancer

1 reference

12 December 2020

Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?

1 reference

12 December 2020

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade

1 reference

12 December 2020

10.1007/S10147-008-0830-Y

Identifiers

DOI

1 reference

5 August 2017

1 reference